Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.
UCB SA has entered into a new multiproject strategic alliance with Cancer Research UK and its innovation arm, Cancer Research Horizons, to advance a pipeline of novel investigational oncology candidates.
A joint Nankai University and Tianjin Accendatech Technology Co. Ltd. patent describes new isoalantolactone derivatives reported to be useful for the treatment of liver cancer.
Solve Therapeutics Inc. has prepared and tested new antibody-drug conjugates (ADCs) comprising a monoclonal antibody targeting trophoblast glycoprotein (TPBG; 5T4) covalently linked to cytotoxic drug and reported to be useful for the treatment of cancer.
SMARCA4-deficient cells have shown dependency on SMARCA2 for survival, suggesting SMARCA2 as a promising synthetic lethal target in SMARCA4-deficient cancers. Chinese researchers recently published data on a series of SMARCA2 PROTACs, among which compound [I] exerted good SMARCA2 degradation.
Simcere Zaiming Pharmaceutical Co. Ltd.’s SIM-0613 for injection has received clinical trial approval from China’s National Medical Products Administration (NMPA), enabling initiation of a clinical trial for advanced solid tumors.
Signadori Bio SAS has successfully completed its seed extension financing round, bringing to €11.1 million (US$13 million) the total raised to support its development of a next-generation, off-the-shelf, in vivo-engineered, monocyte immunotherapy platform to treat solid tumors.
Yuanyi Wise Tech (Ningbo) Ltd. has prepared and tested new tricyclic compounds acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12V mutant) interaction inhibitors potentially useful for the treatment of cancer.
RSS
